These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7462389)

  • 1. Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome.
    Quigley ME; Rakoff JS; Yen SS
    J Clin Endocrinol Metab; 1981 Feb; 52(2):231-4. PubMed ID: 7462389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
    J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dopamine and metoclopramide in polycystic ovary syndrome.
    Barnes RB; Mileikowsky GN; Cha KY; Spencer CA; Lobo RA
    J Clin Endocrinol Metab; 1986 Aug; 63(2):506-9. PubMed ID: 3722335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of gonadotropin and prolactin release by dopamine: effect of endogenous estradiol levels.
    Judd SJ; Rakoff JS; Yen SS
    J Clin Endocrinol Metab; 1978 Sep; 47(3):494-8. PubMed ID: 122409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced disparity of gonadotropin secretion by estrone in women with polycystic ovarian disease.
    Chang RJ; Mandel FP; Lu JK; Judd HL
    J Clin Endocrinol Metab; 1982 Mar; 54(3):490-4. PubMed ID: 6799536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of ovariectomy and estrogen treatment on the dopamine inhibition of gonadotropin and prolactin release.
    Judd SJ; Rigg LA; Yen SS
    J Clin Endocrinol Metab; 1979 Aug; 49(2):182-4. PubMed ID: 572372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation.
    Barnes RB; Lobo RA
    J Clin Endocrinol Metab; 1985 Oct; 61(4):779-82. PubMed ID: 3928677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin release in polycystic ovary.
    Falaschi P; del Pozo E; Rocco A; Toscano V; Petrangeli E; Pompei P; Frajese G
    Obstet Gynecol; 1980 May; 55(5):579-82. PubMed ID: 6768043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relation between hyperprolactinemia and polycystic ovary syndrome].
    Hámori M; Szendei G; Kovács I; Somos P
    Zentralbl Gynakol; 1987; 109(8):481-6. PubMed ID: 3111126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Perić LA
    J Endocrinol Invest; 1988 Apr; 11(4):255-9. PubMed ID: 3137253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naloxone does not interfere with the dopamine-induced decrease in gonadotropin secretion in women with polycystic ovarian disease.
    Paradisi R; Margrini O; Venturoli S; Fabbri R; Porcu E; Stanzani L; Flamigni C
    Horm Metab Res; 1985 Jan; 17(1):29-31. PubMed ID: 3917966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
    Christman GM; Randolph JF; Kelch RP; Marshall JC
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
    J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
    Veldhuis JD; Pincus SM; Garcia-Rudaz MC; Ropelato MG; Escobar ME; Barontini M
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3772-8. PubMed ID: 11502810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevations in unbound serum estradiol as a possible mechanism for inappropriate gonadotropin secretion in women with PCO.
    Lobo RA; Granger L; Goebelsmann U; Mishell DR
    J Clin Endocrinol Metab; 1981 Jan; 52(1):156-8. PubMed ID: 6778890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further evidence against dopamine deficiency as the cause of inappropriate gonadotropin secretion in patients with polycystic ovary syndrome.
    Rosen GF; Lobo RA
    J Clin Endocrinol Metab; 1987 Nov; 65(5):891-5. PubMed ID: 3117832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin levels in the polycystic ovary syndrome.
    Milewicz A
    J Reprod Med; 1984 Mar; 29(3):193-6. PubMed ID: 6233421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating luteinizing hormone pulse frequency in women with polycystic ovary syndrome.
    Kazer RR; Kessel B; Yen SS
    J Clin Endocrinol Metab; 1987 Aug; 65(2):233-6. PubMed ID: 3597703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of LH suppression in polycystic ovary syndrome.
    Fleming R; Black WP; Coutts JR
    Clin Endocrinol (Oxf); 1985 Dec; 23(6):683-8. PubMed ID: 3938353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.